STUB1 and hematologic disorder: Strengths of this study include the large cohort of individuals who underwent both MBL and CHIP screening, with results of both screening assays unknown to study participants, the median follow-up of five years to identify incident hematological cancers, and our manual review process to confirm incident hematological malignancies.